A nonprofit division of Sevadar Foundation Inc.

For clinicians  ·  For facilities  ·  For families  ·  For staff

Why medication burden is an ownership issue

For facility ownership and management

A medication list is a clinical document that produces operational consequences. Those consequences land on you, and several of them are not obviously about medication at all.

Where it shows up first

  • The incident log. Risk in these classes concentrates at initiation, not in steady state. Fall risk was roughly 3.8 times higher in the 24 hours after a benzodiazepine was started in a case-crossover study of 594 long-stay US nursing home residents, mean age 87.5. Fracture risk after starting an opioid in older adults with arthritis is concentrated in the first two weeks. Pneumonia risk after starting an antipsychotic peaks in the first week. Antipsychotic fracture risk in a nationwide cohort of Danes over 65 was measured in the first 30 days.
  • Behavior on the night shift. A resident in pain who cannot report pain presents as agitated. A randomized trial of 352 residents with moderate to severe dementia found a stepwise pain-treatment protocol reduced agitation by an average of 17% over eight weeks — and that agitation worsened again when the pain treatment was withdrawn.
  • Assessment quality. Sedation gets recorded as decline, decline gets attributed to progression, and the care plan adjusts to a person who is not there. That is a documentation problem, a family-relations problem and a care-planning problem at once.
  • Family meetings. A family that has been told their parent is declining, and then discovers a medication started three weeks earlier, has lost confidence in the building — reasonably.
  • Quality measures. The antipsychotic measure is the visible one, and its specification changed on January 1, 2026.

The scale of it, with populations named

  • 23.2% of 211,783 long-stay US nursing home residents aged 65 and over with fee-for-service Medicare met the Beers threshold for central nervous system polypharmacy — three or more concurrent CNS-active medications for more than 30 days — in 2021 data. Gabapentin was the agent most frequently involved.
  • 65.3% of proton pump inhibitor prescriptions among Medicare Part A skilled-nursing admissions to 22 Midwestern US facilities had no appropriate diagnostic code. Even crediting NSAID and anticoagulant prophylaxis, 24% of all admissions were on one with no relevant gastrointestinal diagnosis.
  • 74.0% of 4,023 nursing home residents across 57 facilities in seven European countries and Israel were taking five or more medications; 24.3% were taking ten or more. That is a drug count against no appropriateness criterion.
  • Around a third of residents in pooled international data from 85 papers were subject to physical restraint (33%) or chemical restraint (32%), with bedrails at 44% and benzodiazepines at 42% the most prevalent forms. Those are pooled international proportions across heterogeneous definitions, and North American studies reported lower physical-restraint prevalence. They are not a US figure.

The transmission problem is an ownership problem

The care-plan item that fails most often is the last one: that every staff member working with a resident knows the plan. In a building with agency cover, high turnover or a float pool, that is not a clinical failure — it is a staffing and information-systems failure, and it is squarely yours.

The practical test is not whether a plan exists. It is whether somebody who started three weeks ago can say what settles this resident. Adjusting care plans.

Why non-pharmacological approaches fail in buildings that intend them

Three reasons, all operational rather than clinical.

  1. They take staff time. An approach requiring four unhurried minutes does not exist in a building where nobody has four minutes. This is why staffing ratio is a clinical variable in a memory-care unit rather than a labor line.
  2. They are person-specific, so they only work if the plan travels across every shift.
  3. They are not documented when they work. A redirection that settled someone in four minutes leaves no record. The intervention that succeeded is invisible; the one that failed is in the incident log. So the written history of your building is a record of its failures only — which distorts every review that reads it.

What this does not claim

We publish no savings claims and no financial projections for your facility. Where we cite cost or staffing figures they come from published research describing what care already costs, and they are not a forecast of what you would save. The published figures, with their populations and currency years. The case made here is a care case; the published cost data is context for why the work is worth resourcing, not the argument for doing it.

And no falls promise.

What the evidence does and does not show

Sedating medications impair gait, balance and reaction time, and their labels say so. That part is not in doubt. What has not been shown is that a deprescribing program reduces fall rates — the trials that tested it were small, short, and mostly measured a medication count rather than a fracture. Those are two different questions, and absence of evidence from underpowered trials is not evidence that the drugs do not cause falls. What the evidence actually shows about deprescribing and falls.

Back to the facility track.

References

  1. Berry SD, Placide SG, Mostofsky E, et al. Antipsychotic and Benzodiazepine Drug Changes Affect Acute Falls Risk Differently in the Nursing Home. The Journals of Gerontology Series A. 2016;71(2):273–278. PMID 26248560 · DOI 10.1093/gerona/glv091.
  2. Miller M, Stürmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. Journal of the American Geriatrics Society. 2011;59(3):430–438. PMID 21391934 · DOI 10.1111/j.1532-5415.2011.03318.x.
  3. Knol W, van Marum RJ, Jansen PAF, Souverein PC, Schobben AFAM, Egberts ACG. Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society. 2008;56(4):661–666. PMID 18266664 · DOI 10.1111/j.1532-5415.2007.01625.x.
  4. Torstensson M, Leth-Møller K, Andersson C, Torp-Pedersen C, Gislason GH, Holm EA. Danish register-based study on the association between specific antipsychotic drugs and fractures in elderly individuals. Age and Ageing. 2017;46(2):258–264. PMID 27932365 · DOI 10.1093/ageing/afw209.
  5. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065. PMID 21765198 · DOI 10.1136/bmj.d4065.
  6. Jung H, Liu SH, Hume AL, et al. The Prevalence of Central Nervous System-Active Polypharmacy in US Nursing Homes. Journal of the American Medical Directors Association. 2026;27(6):106178. PMID 41895707 · DOI 10.1016/j.jamda.2026.106178.
  7. Patterson Burdsall D, Flores HC, Krueger J, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. Journal of the American Medical Directors Association. 2013;14(6):429–432. PMID 23583000 · DOI 10.1016/j.jamda.2013.01.021.
  8. Onder G, Liperoti R, Fialova D, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. The Journals of Gerontology Series A. 2012;67(6):698–704. PMID 22219520 · DOI 10.1093/gerona/glr233.
  9. Lee DA, Robins LM, Bell JS, et al. Prevalence and variability in use of physical and chemical restraints in residential aged care facilities: A systematic review and meta-analysis. International Journal of Nursing Studies. 2021;117:103856. PMID 33601305 · DOI 10.1016/j.ijnurstu.2020.103856.
  10. Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open. 2021;11(2):e035978. PMID 33568364 · DOI 10.1136/bmjopen-2019-035978.

Bibliographic records on this page were retrieved from PubMed. Every reference links to its DOI or PubMed record.

Written and medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. Last reviewed . This page is educational. DWARAA does not prescribe, deprescribe, diagnose or treat.